Compare · GRAY vs NVO
GRAY vs NVO
Side-by-side comparison of Graybug Vision Inc. (GRAY) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GRAY and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $192.84B, about 7122.3x GRAY ($27.1M).
- NVO has hit the wire 4 times in the past 4 weeks while GRAY has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for GRAY).
- Company
- Graybug Vision Inc.
- Novo Nordisk A/S
- Price
- $5.65+1016.16%
- $43.19-0.75%
- Market cap
- $27.1M
- $192.84B
- 1M return
- -
- -2.46%
- 1Y return
- -
- -41.47%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 4
- Recent ratings
- 0
- 25
Graybug Vision Inc.
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GRAY
- Amendment: SEC Form S-1/A filed by Graybug Vision Inc.
- Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors
- Graybug Vision Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form EFFECT filed by Graybug Vision Inc.
- SEC Form SC 13D/A filed by Graybug Vision Inc. (Amendment)
- SEC Form SC 13G/A filed by Graybug Vision Inc. (Amendment)
- SEC Form SC 13G/A filed by Graybug Vision Inc. (Amendment)
- Roberts Eric W was granted 91,086 shares, increasing direct ownership by 449% to 111,373 units (SEC Form 4)
- SEC Form SC 13D/A filed by Graybug Vision Inc. (Amendment)
- SEC Form SC 13G filed by Graybug Vision Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S